X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SHASUN PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SHASUN PHARMA VENUS REMEDIES/
SHASUN PHARMA
 
P/E (TTM) x -517.5 123.9 - View Chart
P/BV x 0.1 8.5 1.7% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   SHASUN PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
SHASUN PHARMA
Mar-14
VENUS REMEDIES/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs14394 151.6%   
Low Rs6546 142.5%   
Sales per share (Unadj.) Rs324.2214.2 151.4%  
Earnings per share (Unadj.) Rs6.45.3 120.1%  
Cash flow per share (Unadj.) Rs40.615.8 256.5%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs366.053.3 686.1%  
Shares outstanding (eoy) m12.3456.62 21.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.3 98.2%   
Avg P/E ratio x16.213.1 123.7%  
P/CF ratio (eoy) x2.64.4 58.0%  
Price / Book Value ratio x0.31.3 21.7%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m1,2823,958 32.4%   
No. of employees `0000.9NA-   
Total wages/salary Rs m2512,164 11.6%   
Avg. sales/employee Rs Th4,430.1NM-  
Avg. wages/employee Rs Th278.0NM-  
Avg. net profit/employee Rs Th87.6NM-  
INCOME DATA
Net Sales Rs m4,00012,127 33.0%  
Other income Rs m23229 9.9%   
Total revenues Rs m4,02312,356 32.6%   
Gross profit Rs m7851,009 77.8%  
Depreciation Rs m422594 71.0%   
Interest Rs m344415 82.8%   
Profit before tax Rs m42230 18.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-37-73 50.9%   
Profit after tax Rs m79302 26.2%  
Gross profit margin %19.68.3 235.7%  
Effective tax rate %-87.9-31.7 277.6%   
Net profit margin %2.02.5 79.4%  
BALANCE SHEET DATA
Current assets Rs m2,6066,884 37.9%   
Current liabilities Rs m1,9808,456 23.4%   
Net working cap to sales %15.6-13.0 -120.7%  
Current ratio x1.30.8 161.7%  
Inventory Days Days12862 208.2%  
Debtors Days Days43108 40.1%  
Net fixed assets Rs m5,3534,970 107.7%   
Share capital Rs m123113 108.9%   
"Free" reserves Rs m4,3932,875 152.8%   
Net worth Rs m4,5163,020 149.5%   
Long term debt Rs m1,6181,817 89.0%   
Total assets Rs m8,29113,347 62.1%  
Interest coverage x1.11.6 72.3%   
Debt to equity ratio x0.40.6 59.5%  
Sales to assets ratio x0.50.9 53.1%   
Return on assets %5.15.4 94.9%  
Return on equity %1.810.0 17.5%  
Return on capital %6.313.3 47.2%  
Exports to sales %046.4 0.0%   
Imports to sales %18.414.2 129.2%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs m7361,728 42.6%   
Fx inflow Rs m05,843 0.0%   
Fx outflow Rs m7362,173 33.9%   
Net fx Rs m-7363,669 -20.1%   
CASH FLOW
From Operations Rs m997398 250.8%  
From Investments Rs m-461-1,635 28.2%  
From Financial Activity Rs m-5711,309 -43.6%  
Net Cashflow Rs m-3571 -49.3%  

Share Holding

Indian Promoters % 32.9 39.2 83.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 3.6 5.0%  
FIIs % 0.6 17.6 3.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 39.6 167.7%  
Shareholders   20,121 20,750 97.0%  
Pledged promoter(s) holding % 36.4 12.3 295.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   FDC LTD.  FULFORD INDIA  CIPLA  AJANTA PHARMA  UNICHEM LAB  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade on a Negative Note; Sensex Down Over 160 Points(12:30 pm)

After opening the day marginally higher, share markets in India witnessed selling pressure and are presently trading on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


May 21, 2018 03:35 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - SANOFI INDIA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS